In its published draft guidelines, the National Institute for Health and Care Excellence (NICE) has recommended AstraZeneca's (LON: AZN) Fasenra (benralizumab) as a treatment for people with severe eosinophilic asthma, Pharma Times reported on Monday.
The recommendation states that the drug can be an option for treating the condition when standard therapies, such as inhaled corticosteroids and beta-agonists, have failed.
According to NICE, Fasenra is cost-effective for people who have had at least three exacerbations in the last year, when the blood eosinophil count is 400 or more cells per microlitre, and only when biological treatment mepolizumab is not appropriate.
Fasenra is a monoclonal antibody that recruits the body's natural defences to deplete eosinophils. It was approved by the EU in January, making it the first respiratory biologic medicine with an eight-week maintenance dosing schedule.
NICE's approval was based on results from the WINDWARD programme, which include the pivotal Phase III exacerbation trials, SIROCCO and CALIMA, and the Phase III OCS-sparing trial, Zonda.
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Illumina's GRAIL divestment plan receives EC approval
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Ondine Biomedical's Steriwave approved for use by HCA UK
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial
Syros receives Fast Track Designation from FDA for tamibarotene in AML